Life Technologies Corp. has introduced its Applied Biosystems™ AcroMetrix® KRAS FFPE Process Controls, the only on the market that enable laboratories to assess/monitor an entire workflow from FFPE sample to result without using archived tumor material.
The controls are designed to emulate FFPE laboratory samples through all steps of the workflow process, including deparaffinization and extraction. The kit comprises controls for seven of the most commonly assayed KRAS gene mutations: G12A, G12C, G12D, G12R, G12S, G12V, G13D and a wild type (WT) control.
The American Society for Clinical Oncology recommends that all patients diagnosed with metastatic colorectal cancer who are candidates for anti-EGFR therapy be tested for KRAS mutations in a CLIA laboratory to predict drug efficacy.
AcroMetrix® KRAS FFPE Process Controls are manufactured by mixing KRAS mutation-positive cells with a co-polymer, creating a synthetic tissue, which is then formalin-fixed and paraffin-embedded. The kit consists of eight vials, each containing a 10 µm FFPE tissue section created from cells harboring a single mutation; each 10 µm section contains >200 ng of DNA. All AcroMetrix® products are manufactured in accordance with ISO 17511 for consistent performance across lots. The above referenced KRAS FFPE Process Controls products are for Research Use Only.